There remains a severe shortfall of medical oncologists who are capable of a comprehensive study of clinically-relevant problems with human specimens in the laboratory, successful design and conduct clinical trials to improve prevention, detection, and treatment of human cancer, and very importantly, the translation of fundamental knowledge from the bench to the clinic. The shortage of medical oncologists over the next ten years continues. M. D. Anderson Cancer Center is well-suited to host a comprehensive training program that has the capability to reduce the severity of this shortfall.
The specific aims and overall objectives of this program remain unchanged: to train and nurture medical oncology fellows to ensure they are equipped to become the next leaders in every aspect of academic medical oncology. The training program herein provides three research training tracks for medical oncologists. The first track, the clinician investigator track provides training focused on development and implementation of clinical trials and associated correlative studies. The second track is the physician/scientist track which provides training for laboratory-based oncology research. And the third track is our community-based research track which takes advantage of our institution's extensive programs in cancer control and prevention. Fellows who complete this training program will be eligible for certification in the subspecialties of medical oncology and/or hematology. In addition, they will be able to provide the best hematology and medical oncology care available and also develop and lead independent research programs, conduct hypothesis-driven research, communicate their research findings through public presentations and publications in peer-reviewed journals, and obtain peer-reviewed grant support for their work.

Public Health Relevance

This goal of this program is to provide training for the next generation of medical oncologists to perform cancer research, develop new approaches to treat and prevent cancer, and to treat cancer patients and survivors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009666-19
Application #
8456210
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
1994-09-30
Project End
2015-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
19
Fiscal Year
2013
Total Cost
$328,659
Indirect Cost
$27,804
Name
University of Texas MD Anderson Cancer Center
Department
Surgery
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Wu, Sherry Y; Rupaimoole, Rajesha; Shen, Fangrong et al. (2016) A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun 7:11169
Matrana, Marc R; Bathala, Tharakeswara; Campbell, Matthew T et al. (2016) Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin BJU Int 118:264-71
Mougalian, Sarah S; Hernandez, Mike; Lei, Xiudong et al. (2016) Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol 2:508-16
Qu, Jin; Yu, Hongtao; Li, Fenge et al. (2016) Molecular basis of antibody binding to mucin glycopeptides in lung cancer. Int J Oncol 48:587-94
Wargo, Jennifer A; Reddy, Sangeetha M; Reuben, Alexandre et al. (2016) Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 41:23-31
Xing, Yan; Zhang, Jianjun; Lin, Heather et al. (2016) Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer 122:534-45
Huang, Yan; Lichtenberger, Lenard M; Taylor, Morgan et al. (2016) Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther 15:2894-2904
Peng, Weiyi; Chen, Jie Qing; Liu, Chengwen et al. (2016) Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6:202-16
Lou, Yanyan; Pecot, Chad V; Tran, Hai T et al. (2016) Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer 17:e5-11
Chen, Guo; McQuade, Jennifer L; Panka, David J et al. (2016) Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol 2:1056-64

Showing the most recent 10 out of 98 publications